Cancer treatment: Biocon unveils new biosimilar to fight colorectal, other cancers

By: | Published: November 24, 2017 3:54 AM

Biopharma major Biocon on Thursday announced the launch of its new biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India.

Biocon, Biopharma major, biosimilar bevacizumab, cancers in india, Krabeva monoclonal antibody, IPSOS June MAT 2017 data, metastatic colorectal cancerThe brand Krabeva monoclonal antibody developed by Biocon will help expand cancer patients’ access to biosimilar Bevacizumab. (Website)

Biopharma major Biocon on Thursday announced the launch of its new biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers in India. The brand Krabeva monoclonal antibody developed by Biocon will help expand cancer patients’ access to biosimilar Bevacizumab. “It is the world’s first and only bevacizumab with a unique ‘qual-check’ mechanism, which will ensure that patients get a quality-ascertained product right up to infusion,” the company said in a press release.  “We intend to provide a high quality, world-class biosimilar bevacizumab as an affordable therapy option for patients of various types of cancer. We believe Krabeva will be an important addition to our oncology portfolio of novel biologics as well as biosimilars, which are making a significant impact in the realm of cancer care in India,” said Arun Chandavarkar, CEO & joint managing director, Biocon. Global sales of the innovator product in 2016 were pegged at $6.9 billion. The market size for bevacizumab, both innovator product and biosimilars, in India is estimated at Rs 177 crore ($27 million), according to IPSOS June MAT 2017 data.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition